Applications of 4-(5-Bromo-2-Thienyl)-1,3-Thiazol-2-Amine in Industrial Manufacturing

4-(5-Bromo-2-Thienyl)-1,3-Thiazol-2-Amine finds critical applications in selected, high-value industrial sectors as a building block for advanced organic synthesis. The compound’s heterocyclic structure and brominated thiophene group enable performance and conformity with specific regulatory and production demands. Our manufacturing focus ensures reproducible purity and consistent supply for demanding downstream processes. Below, we outline the principal application sectors utilizing this specialty intermediate, with details on compliance, dosage, production integration, and final product forms.

1. Active Pharmaceutical Ingredient Synthesis (Thiazole-Linked Candidates)

Leading pharmaceutical manufacturers use 4-(5-Bromo-2-Thienyl)-1,3-Thiazol-2-Amine as a core intermediate in the synthesis of selective kinase inhibitors and anti-infective agents. The compound often serves in transition-metal-catalyzed coupling reactions and heterocycle extension, allowing late-stage diversification. The material’s lot-to-lot consistency ensures traceability for regulated cGMP operations.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• European Pharmacopoeia monographs for process intermediates, as applicable
• USP General Chapter <797>, Risk Assessment for API Production
• FDA 21 CFR Part 211 for finished drug quality

Typical usage ratio

• 0.08 – 0.3 molar equivalents per API target batch, based on stoichiometric requirements and impurity profile control
• Ratio fine-tuned during process validation to minimize residual brominated by-products in final pharmaceutical compounds

Downstream process integration

• Incorporated during early-stage coupling or cyclization step after selection of complimentary aryl halides or amines
• In-process controls include HPLC purity checks and trace element analysis on isolation
• Integrated waste management for bromide residual removal according to pharmacopeia

Final product types

• Thiazole-based kinase inhibitors (e.g., preclinical anticancer leads)
• Antiviral and antibacterial pharmaceutical actives with heterocyclic scaffolds
• Custom manufactured intermediates for generic API portfolios
• Advanced research compounds for pharmaceutical discovery platforms

2. Agrochemical Active Compound Development

Major crop protection manufacturers employ this compound for the synthesis of novel thiazole- and thiophene-based fungicides and insecticides. The brominated heterocycle imparts selectivity and persistence against resistant pest populations, particularly in seed treatment and foliar formulations. Its controlled reactivity supports reliable scale-up and environmental compliance.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP) in agrochemical synthesis
• EC Regulation No 1107/2009 (Plant Protection Products Regulation)
• FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act, US EPA)
• ISO 9001:2015 quality system implementation for agrochemical intermediates

Typical usage ratio

• 0.1 – 0.25 mole fraction of input reactants in heterocycle extension for new actives
• Dosage adapted as per required selectivity, assessed by bioassay and registration batch data

Downstream process integration

• Used during the key cyclization or Suzuki coupling prior to functionalization with pesticide-specific side chains
• Batch-wise QC with GC-MS for impurity tracking and confirmation of residual bromine content compliance
• Environmental loading assessed for manufacturing process by effluent monitoring

Final product types

• Seed treatment fungicides with enhanced persistence
• Systemic insecticides targeting sap-feeding pests in field crops
• Research leads in herbicidal mode-of-action programs
• Custom intermediates for formulation optimization studies

3. Advanced Electronic Chemical Synthesis (Organic Semiconductor Precursors)

Fabricators of organic semiconductors and functional materials select this aminothiazole for integration into π-conjugated frameworks. Its brominated thiophene moiety offers anchor points for further coupling in the design of hole-transport materials or organic field-effect transistor (OFET) layers. Ultra-high purity lots support low-defect optoelectronic performance in thin-film deposition processes.

Industry compliance standards

• IPC-6012 (Qualification and Performance Specification for Rigid Printed Boards)
• SEMATECH quality assessments for organic electronic materials
• RoHS Directive 2011/65/EU compliant for hazardous substances control
• ISO 14001 environmental controls for specialty chemical manufacturing

Typical usage ratio

• 0.08 – 0.15 molar input per oligomeric synthesis batch, adjusted for polymer molecular weight target and throughput
• Ratios agreed with downstream R&D based on charge mobility test results

Downstream process integration

• Entering via metal-catalyzed cross-coupling or sequential polycondensation, introduced after monomer protection and activation steps
• TLC, NMR, and elemental analysis at each integration step
• Finished product further purified by GPC or vacuum distillation before device use

Final product types

• High-performance π-conjugated polymers for OFETs
• Organic photovoltaic (OPV) absorber and donor materials
• Specialty dyes for OLEDs
• Charge-transport segment intermediates for printed electronics

4. Specialty Dye Manufacturing for Life Sciences

Producers using custom thiazole derivatives as fluorescent probes and enzyme labeling reagents apply this raw material to synthesize dye molecules with controlled emission wavelengths and reactive functional groups. The amine and bromothiophene functionalities provide access to target molecules in diagnostics and cell imaging. Our QC protocols support lot traceability for application in sensitive biotechnical platforms.

Industry compliance standards

• REACH Regulation EC No 1907/2006 substance registration
• ISO 13485 for production of chemicals used in medical/life science applications
• OECD Principles of Good Manufacturing Practice (GMP) for diagnostic reagents
• CLP Regulation (Classification, Labeling and Packaging of Substances and Mixtures)

Typical usage ratio

• 0.05 – 0.12 molar input in initial dye-forming reaction, dependent on quantum efficiency and hydrophilicity requirements
• Dosage adjustments refined after emission spectrum analysis

Downstream process integration

• Feeds into diazotization or amide coupling in stage two of dye assembly
• Purity monitored by HPLC, UV-vis, and LC-MS
• Reagent introduced after pre-functionalization to minimize side-product development

Final product types

• Fluorescent bioprobes for microscopy
• Enzyme-linked immunoassay (ELISA) labeling dyes
• Reactive intermediates for flow cytometry stains
• Non-destructive cell imaging agents